Blood tests have recently emerged as a new alternative for the detection of AD biomarkers such as phosphorylated tau protein, amyloid beta or neurofilaments, although distinction between AD and non-related dementias can be challenging due to similar biomarkers [6]. This evidence concerns the gene MAPT and Alzheimer disease.